2Silverman LR.Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes(MDS)[J].Oncologist,2001,6:8-14.
3Adams CD,Szumia PM,Baroletti SA,et al.Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome[J].Pharmacotherapy,2005,25:765-768.
4Hueser C,Patel AJ.Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome[J].Pharmacotherap,2007,27:1759-1762.
5Sekhri A,Palaniswamy C,Kurmayagari K,et al.Interstitial lung disease associated with azacitidine use:a case report[J].Am J Ther,2012,19:e98-e100.
6Nair GB,Charles M,Ogden L,et al.Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome[J].Respir Care,2012,57:550-556.
7Pillai AR,Sadik W,Jones PA,et al.Interstitial pneumonitis:an important differential diagnosis for pulmonary sepsis in haematology patients[J].Leuk Res,2012,36:e39-e40.
8Hayashi M1,Takayasu H,Tada M,et al.Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome:first case report in Japan[J].Intern Med,2012,51(17):2411-2415.
9Parker MI,Gevers W.Demethylation of the type I procollagen genes in transformed fibroblasts treated with 5-azacytidine[J].Biochem Biophys Res Commun,1984,124:236-243.
10Umemura S,Yamane H,Suwaki T,et al.Interstitial lung disease associated with gemcitabine treatment in patients with non-smallcell lung cancer and pancreatic cancer[J].J Cancer Res Clin Oncol,2011,137:1469-1475.
